Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Giuseppe Ronzitti**, David-Alexandre Gross† and Federico Mingozzi**

1 INTEGRARE, Genethon, InsERM, Univ Evry, Université Paris-Saclay, Evry, France, 2 Spark Therapeutics, Philadelphia, PA, United States

Keywords: AAV vectors, gene therapy, T cells, B cells, clinical trials

INTRODUCTION

Adeno-associated virus (AAV) is a small (25 nm), non-enveloped virus composed of an icosahedral capsid that contains a single-stranded, 4.7-Kb DNA genome. AAVs are Dependovirus, as they replicate only in the presence of helper viruses such as adenovirus, herpes virus, human papillomavirus and vaccinia virus (1–4). AAV genome is composed by two genes rep and cap, flanked by two palindromic inverted terminal repeats (ITR). Rep encodes for proteins involved in replication of the viral DNA, packaging of AAV genomes, and viral genome integration in the host DNA (5). Cap encodes for the three proteins that form the capsid, VP1, 2 and 3, and for the assembly activating protein (AAP) and the newly identified MAAP (5, 6). Wild-type AAVs naturally infect humans around 1 to 3 years of age (7–9) and are not associated with any known disease or illness (10). After infection, AAV remains latent in integrated or not-integrated forms, until a helper virus provides the functions necessary for its replication (5). In recombinant AAV vectors (rAAV), the parental virus rep and cap genes are replaced with the DNA of choice flanked by the two ITRs, and referred to as the transgene expression cassette when used for gene therapy purposes. rAAV vectors are produced efficiently by several approaches: transient double or triple transfection of mammalian cells (11, 12); infection of mammalian cell lines with adenovirus (13) or herpes simplex virus (14, 15); and infection of insect cells with baculovirus (16). During packaging, rep and cap genes are
provided in *trans* together with the adenoviral helper proteins required for AAV genome replication and packaging (17, 18). Triple transfection of HEK293 cells is one of the most commonly used methods for rAAV production. It is based on the co-transfection of three plasmids: one containing the transgene expression cassette flanked by the viral ITRs, a second packaging plasmid expressing the rep and cap genes and a third plasmid encoding for adenoviral helper genes (17, 19). Historically, the purification of rAAV vectors was performed by ultracentrifugation in two successive density gradients (17). Nowadays, the purification of AAV capsids by affinity chromatography is more frequently used as column process is more scalable and yields high purity preparations that are amenable for clinical use (20). Based on the purification method, rAAV preparations differ in terms of contaminants and the ratio of empty to full capsids. An important focus in the field is the continuous improvement of the rAAV manufacturing processes to increase vector yields and purity while reducing costs (17, 18, 21, 22). A significant concern related to the methods of production and purification is the impact of rAAV purity on the overall vector immunogenicity profile. One obvious example of contaminant is the presence of empty capsid in rAAV preparations (23).

The protein capsid of rAAV affects the affinity of the vector for a given tissue. Transduction of a cell by rAAV vectors requires the interaction of the viral capsid with surface receptors followed by internalization and intracellular trafficking through the endocytic/retromolecular compartment. Capsid proteins then mediate the endosomal escape and nuclear import, and after uncoating, the single stranded genome carried by rAAV is converted to a double stranded DNA. This conversion step may represent a limiting factor to gene transfer that self-complementary (sc) AAV vectors could bypass at the cost of reduced packaging capacity (24). Different from wild-type AAV, the genome of rAAV vectors inefficiently integrates into the host DNA and remains mostly episomal (10, 25, 26). Transgene expression finally results from the transcription of the mRNA and the successive translation of the transgene coding sequence (Figure 1) (27).

To date, 13 different AAV serotypes and 108 isolates (serovars) have been identified and classified (5, 28). The relatively low complexity of AAV biology facilitates production of rAAV vectors composed by a transgene expression cassette flanked by the ITRs from serotype 2 (29) pseudotyped into any of the available AAV capsid variants (5). This process allows a comparison of the properties conferred to rAAVs by the capsid proteins e.g., tissue targeting, potency or immunogenicity. In particular, the capsid composition influences the first steps of transduction i.e., interactions with receptors on target cells and impact, post-entry trafficking and endosomal escape. Therefore, rAAV vectors bearing different capsids have different transduction potential, but also potentially different immunological properties (5, 30). In recent years, several approaches have been used to enable the generation of engineered rAAV vectors and a significant expansion of the rAAV vector toolkit (31–34). While the increasing knowledge on rAAV capsid structure-function (35) led to the generation of capsid variants by direct mutagenesis of specific amino acid residues, the development of rAAV capsid libraries and high-throughput screening methods resulted in the generation of a variety of novel capsids by directed evolution (31). Recently, two different approaches were reported to overcome the limitations of "conventional" methods of vector evolution. Both methods take advantage of the latest advancements in DNA synthesis and sequencing, and are aimed at the reduction of the complexity of the initial library to be screened either by artificial intelligence (6) or by grafting peptides derived from a subset of proteins involved in specific cellular functions (36). Regardless of the method used, the isolation of new rAAV vector capsids responds to a precise need of increased transduction efficacy with optimized biodistribution and reduced immunogenicity, at least in terms of cross-reactivity with pre-existing antibodies.

Despite the efforts dedicated to the enhancement of transduction efficacy, several challenges for clinical use of rAAV vectors remain. Among them, vector immunogenicity, which reflects the interactions of rAAVs with the host immune system, is perhaps of the utmost relevance given its impact on the outcomes of treatment in terms of transgene expression durability, and to the ability to eventually re-administer the vector in case of loss of efficacy over time (Figure 2). Here, we will outline general concept on rAAV vector immunogenicity, and comprehensively discuss the clinical experience in the context of systemic vector administration for liver-targeted gene therapy trials for hemophilia and for the treatment of neuromuscular diseases.

**HUMAN IMMUNE RESPONSES TO WILD-TYPE AAV**

**Humoral Immunity to AAV**

Although AAV seroprevalence varies geographically, neutralizing antibodies (NAbs) that recognize virtually all AAV serotypes can be found in a large proportion of the human population (ranging from 30 to 60%). Successive infections may explain the high prevalence of anti-AAV NAbs in humans (37–39), resulting in broad cross-reactivity across AAV serotypes of different origins, including human, mammalian or engineered. Regardless of the geographic region, the most prevalent NAbs are directed against AAV2, followed by AAV1 (38). NAbs appear early in childhood with a peak at 3 years of age, leaving a short time-window that is potentially convenient for gene transfer between 7 and 11 months, after the infant loses humoral protection by passive transfer of maternal antibodies (38).

While production of Abs from all four IgG subclasses have been observed, IgG1 is the predominant subclass found in seropositive individuals and, in general, titers of anti-AAV IgG antibodies correlate with the those of anti-AAV neutralizing antibodies (40, 41). Similarly, subjects undergoing gene transfer with AAV vectors develop anti-AAV antibodies from all the four IgG subclasses (mainly IgG1 but also IgG2 and IgG3) as well as IgM, concurring to the
Immunological barriers to gene transfer. (1) Pre-existing neutralizing antibodies to AAV vectors reduce gene transfer efficacy. (2) Capsids can be recognized by TLR2 at the surface of the cells thus triggering innate immune responses. (3) After endocytosis, the viral genome can stimulate TLR9-mediated innate immunity. (4) Transgene expression may be associated to the development of an immune response that impacts the outcome of the gene therapy. (5) Capsid proteins can be degraded by proteasome and presented on MHC class I. (6) Capsid proteins can be presented on MHC class II. (7) After presentation on MHC class I, capsid-specific cytotoxic CD8+ T cells can clear transduced cells. (8) After presentation on MHC class II, anti-capsid humoral response prevents further vector re-administration.

resulting high neutralizing titers (42). Interestingly, some individuals carry non-neutralizing IgG binding to the AAV capsid (43). While even low-titer NAbS are associated with efficient vector neutralization in vivo (44–46), the presence of binding non-NAbs appear to enhance rAAV transduction efficacy, at least in some tissues (43). Pre-existing anti-AAV antibodies in individuals receiving rAAV vectors are being investigated as a potential source of toxicity related to complement activation (47) although a direct interaction of rAAV vectors with complement proteins was also reported (48, 49).

T Cell Responses to AAV

Early clinical trials of gene transfer with rAAV demonstrated the potential negative impact of T cell-mediated immunity on the outcome of gene transfer (45, 50, 51). Since then, research efforts have been focused on the study of pre-existing anti-AAV cell response and on the development of methods to detect and monitor cell-mediated immunity in AAV-based gene transfer (52–55).

Different assays were developed to estimate the frequency of T cells specific for AAV in humans, including IFN-γ ELISPOT (56–58) and flow cytometry based assays (52, 56, 58). In general, AAV-specific cellular responses are less frequently observed than humoral responses, probably due to the lower assay sensitivity and to the fact that capsid-reactive lymphocytes are found in low frequency in peripheral blood. This may explain why different independent studies reported a lack of correlation between pre-existing cellular and humoral immune responses (50, 56, 58). Indeed, efficient AAV-specific T cells detection in peripheral blood and spleen requires several rounds of in vitro expansion with peptide libraries derived from the capsid VP1 (50, 56). Alternatively, FACS staining after an AAV specific tetramer-mediated magnetic enrichment can be used to increase the detection of AAV-specific T cells (59). Recently, we showed a correlation between anti-AAV antibodies and circulating
γ-activated NK cells, which secrete both IFN-γ and TNF-α, without a cytotoxic phenotype, in the context of gene transfer trials. As observed with humoral responses, capsid T cell responses are less frequent in young children (<5 years) compared to older healthy donors (56, 60), suggesting that anti-AAV immune responses may arise during infancy after AAV infection, and persist throughout lifetime as a pool of memory T cells in secondary lymphoid organs. Consistently, differentiation markers measured at single cell level by flow cytometry indicated that the majority of AAV-specific T cells found in humans present a memory phenotype (50, 52, 53, 58). After exposure to the capsid antigen, AAV-specific memory T cells produce IFN-γ, IL-2 and TNF-α, and acquire a cytotoxic phenotype measured by the expression of granzyme B and CD107a degranulation markers (52, 53, 56, 58). In addition to that, two patterns of cellular responses to AAV that are dependent on the serology status of patients were recently identified by our laboratory (61). Exposure of human peripheral blood mononuclear cells (PBMCs) obtained from AAV-seropositive donors to capsid epitopes induced an effector memory phenotype in activated CD8+ T cells, with secretion of TNF-α, and expression of granzyme B and CD107a (52). In seronegative patients, transient activation of Natural Killer (NK) cells, but not naïve CD8+ T cells, was observed. The role of these activated NK cells, which secrete both IFN-γ and TNF-α without a cytotoxic phenotype, in the context of gene transfer remains unknown.

POST-TREATMENT IMMUNE RESPONSES AGAINST AAV VECTORS

Innate Immunity of rAAV

Vectors derived from AAV are constituted by a protein capsid, which is highly similar, if not identical, to that of wild type AAV, a single or double stranded DNA genome that does not express any viral proteins, and the inverted terminal repeats (ITR), GC-rich regions of the single stranded genome with a complex secondary structure. Both the capsid and the DNA components of rAAV may concur in the activation of innate immunity along with other host-specific factors (Figures 2, 3). In addition to that, production and purification of the vectors lead to the presence of DNA-depleted AAV capsids (empty capsids) and both DNA and protein contaminants. In comparison to other biological drugs such as monoclonal antibodies, rAAV are quite complex and the prediction of the immune-mediated toxicities after vector administration remains elusive, partially because of the lack of fully predictive animal models (62–64).

In recent years, significant research efforts were focused on establishing a causative role of innate immunity in the immune-mediated toxicities observed in humans. However, the intrinsic characteristics of the innate immune system, together, and the lack of clinical evidence of innate immune system activation still represent a challenge toward the appraisal of the innate immunity role in the immune-mediated toxicities observed in gene therapy trials.

Innate immunity is the first barrier against pathogens as it mounts rapidly and does not require a specific adaptation to the pathogens. Innate immune response depends on the recognition of pathogen-associated molecular patterns by the pattern recognition receptors (PRRs) expressed by immune cells. The molecular recognition of viral nucleic acids, membrane glycoproteins, or even chemical messengers by PRRs leads to the nuclear translocation of Nuclear Factor κB (NF-κB) and Interferon-Regulatory Factor (IRF), transcription factors with a central role in the expression of pro-inflammatory cytokines, or type I interferons (IFNs), respectively (65).

In the context of rAAV-mediated gene transfer, preclinical studies supported the important role of type I IFNs in the induction of CD8+ T cell responses. In particular, blocking the activation of innate immune responses prevented both cytotoxic (66, 67) and humoral (52) anti-capsid responses in vivo.

Most of the data on the role of type I IFNs in rAAV vectors immunogenicity were obtained in the context of liver-targeted gene transfer. The liver represents a unique immunological environment, characterized by the presence of resident immune cells together with both specialized and non-specialized antigen presenting cells (APCs). In non-parenchymal liver cells, including Kupffer cells and liver sinusoidal endothelial cells (LSECs), innate immunity activation after liver gene transfer with rAAV mainly occurs through binding to TLR2 expressed on the cell surface (68). The rAAV double-stranded DNA genome, and in particular its unmethylated CpG motifs, may be recognized by the endosomal
TLR9 in either Kupffer cells (69), peripheral plasmacytoid DCs (pDCs) (66, 70) or monocyte-derived DCs (71). TLR9 engagement was associated with enhanced activation of AAV-specific CD8+ T cell due to increased antigen presentation on class I major histocompatibility complex (MHC) (54, 66, 72).

An intriguing hypothesis is that, in addition to the vector DNA genome, double-stranded RNA (dsRNA) may participate to the induction of innate immunity to rAAV (73). According to this study, dsRNAs are produced by the promoter activity of the ITRs. Accumulation of dsRNAs would, in turn, stimulates the MDA5 sensor in human hepatocytes transduced with AAV, leading to the expression of type I IFNs. Interestingly, the blockade of MDA5 decreased the IFN response and improved transgene expression in transduced cells in vitro (73). Although this hypothesis is not yet supported by clinical data, it may explain why cellular responses are sometimes initiated weeks after vector administration in clinical trials, a timeframe that is consistent with the dsRNA synthesis in vivo (51, 74).

### Adaptive Immune System Activation Following rAAV Administration

The induction of an adaptive immune response requires a longer time than innate immunity and is considered as the second barrier toward pathogens. On the other hand, adaptive immune responses are antigen-specific and eliminate pathogens while generating an immunological memory.

T and B lymphocytes are activated after the molecular recognition of an antigen presented by APCs (75). After activation, lymphocytes expand and differentiate into effector cells and specifically inactivate or clear antigens through the induction of humoral or cytotoxic responses. When the levels of circulating antigen are reduced by the mounting immune response, memory T and B lymphocytes are generated and can respond to successive antigenic stimulation in a more efficient and faster manner (75). After rAAV vector administration, both transduced cells and professional APCs present capsid-derived epitopes to cytotoxic CD8+ T cells via MHC class I (50, 56, 66, 76). Activated CD8+ T cells may clear rAAV-transduced cells thus inducing inflammation in the target organ, affecting the gene transfer outcome (45, 51, 77, 78). The concurrent presentation of capsid-derived MHC class II epitopes by professional APCs activates CD4+ T helper cells, which facilitate humoral and cell-mediated immune responses (67). Indeed, experience from clinical trials indicate that rAAV vectors administration leads to the development of anti-AAV IgG and NAb (42), likely preventing vector readministration. Administration of immunomodulatory regimens (79) or, B-cell depletion prior to gene transfer, (80) have been effective in blocking humoral immune responses to rAAV in the preclinical setting. To this aim rituximab in combination with rapamycin is currently being tested in humans as a strategy to enable vector re-dosing (NCT02240407).

Clinical experience indicates that, to some extent, rAAV vector immunogenicity is dose-dependent (81, 82). Low vector doses appear to be managed, in most cases, by short courses of corticosteroids or other mild immunosuppressive regimens with rescue of transgene expression (82). Accordingly, a dose-dependent increase in AAV-antigen presented on MHC class I together with higher CD8+ T cells activation was reported in vitro (76, 83). Nevertheless, deleterious effects of anti-capsid cellular response, and in particular the very slow onset of the T cell response, are not fully recapitulated by animal models. This has prevented the investigators to formulate predictive models of rAAV vector immunogenicity, and to some extent hindered the development of specific immunomodulatory protocols specific for gene transfer.

### IMMUNE RESPONSES AGAINST THE TRANSGENE PRODUCT

A large part of the gene therapy strategies for monogenic diseases aim at the replacement of a mutated gene with a corrected copy to restore its function and correct the disease phenotype. The potential development of an immune response against the transgene is dependent on several variables, including the tissue targeted with gene transfer, the host genetic background, and the extent of the residual expression of the donated gene. Gene transfer in a context of missense mutations and residual endogenous expression of the full length protein is unlikely to induce anti-transgene immune responses, although some preclinical studies suggest that even single amino acid variations can be recognized by the host immune system (84). Conversely, gene transfer in the context of stop mutations with no residual protein expression, is potentially more likely to result in anti-transgene immunity due to the absence of central tolerance against the transgene product itself.

In the clinical setting, anti-transgene immune responses were documented, so far, in only few clinical trials, mostly after intramuscular delivery of rAAV vectors. In particular, evidence of T cell-mediated anti-transgene cytotoxic T cell responses was documented in a phase I/II trial of intramuscular gene transfer in Duchenne muscular dystrophy patients (85). In this trial, AAV-mediated transfer of a mini-dystrophin transgene resulted in poor expression and was associated with the development of T cell responses directed against transgene epitopes or, possibly, in the recall of pre-existing anti-dystrophin T cells response. Similarly, decreased transgene expression and transgene-specific cytotoxic T cells were reported after intramuscular delivery of alpha-1 antitrypsin with rAAV vector in one subject (86), although most of the clinical trial participants achieved long-term expression of the transgene (87). In other clinical trials, the impact of immune response on the treatment outcomes was less clear. Finally, in a phase I/II trial of intracranial delivery of a rAAV5 vector for mucopolysaccharidosis type IIIB, anti-transgene T cells were also reported (88). Taken together, the clinical data presented suggest that disease-specific conditions e.g., the ongoing inflammation in muscle dystrophies (85), are likely to increase transgene immunogenicity after gene transfer. The apparent inconsistency between the potential immunogenicity of the transgene and the low number of actual reports of anti-transgene immunogenic responses could possibly be explained also by the fact that most of the clinical
of CD8+ immunity (107, 108). Other mechanisms like the induction of Tregs play an essential role in tolerance induction through the induction of T regulatory cells (Tregs) (104, 105). Tregs can also act as professional APCs and promote tolerance, compared to other professional APCs (95, 96). Another layer of complexity in the evaluation of the potential immunogenicity of gene transfer is that, in some tissues, such as muscle (91), the presence of inflammation due to the underlying disease might result in a higher risk of triggering transgene-directed immune responses. Conversely, in tissues that are defined as immune-privileged per se due to the presence of barriers that reduce antigen presentation and immune system cells trafficking (e.g., the eye or the nervous system) or to their particular immunological milieu (e.g., the liver), the overall risk of encountering anti-transgene immune responses is low.

The liver, due to the constant exposure to non-self antigens, has peculiar immunological properties that prevent uncontrolled immune activation. Several studies of gene transfer with rAAV in both small and large animals indicated that hepatocyte-restricted transgene expression induced a robust, antigen-specific peripheral tolerance (60, 92, 93). In animal models, liver-induced immunological tolerance has been exploited to counteract deleterious immune responses induced by gene transfer targeting more immunogenic tissues, such as the muscle (89, 94). The different antigen presenting cells (APCs) resident in the liver are involved in the tolerogenic effect after liver gene transfer. In particular, Kupffer cells, the macrophages resident in the liver, seem to have a less mature phenotype compared to other professional APCs (95, 96). This, together with the secretion of the anti-inflammatory cytokine IL-10 (97–99) by Kupffer cells leads to poor T cell activation. Antigen presentation through MHC class I expressed onto hepatocytes has been associated with incomplete CD8+ T cell activation and increased exhaustion and apoptosis (89, 93, 94, 100–103). Liver sinusoidal endothelial cells (LSECs) can also act as professional APCs and promote tolerance through the induction of T regulatory cells (Tregs) (104, 105). Tregs play an essential role in tolerance induction after liver gene transfer as demonstrated by the increased transgene immunogenicity observed after Tregs depletion (60, 89, 92, 106). Consistently, increased Tregs expansion by rapamycin treatment, favored the induction of liver-mediated tolerance even in the presence of pre-existing anti-transgene immunity (107, 108). Other mechanisms like the induction of CD8+ regulatory T cells (109), the degradation of T cells in hepatocytes (110), and the CD4+ T cell anergy (111) were proposed in the establishment and maintenance of liver tolerance.

**IMMUNE RESPONSES TO rAAV VECTORS IN CLINICAL TRIALS AFTER INTRAVENOUS INFUSION OF rAAV VECTORS**

**Liver Gene Transfer – The Experience With Hemophilia B**

The largest set of clinical data available on rAAV-mediated gene transfer for the treatment of liver diseases derives from hemophilia B studies. Hemophilia B is an ideal target for rAAV gene therapy for different reasons. First, the transgene, human coagulation factor IX (hFIX), can be expressed in a variety of tissues including muscle and liver, the latter being its natural site of synthesis, and low levels of transgene expression (around 5% of normal) are sufficient to greatly reduce the impact of the disease on the quality of life of the patients. Another important advantage is that hFIX is small and, based on the experience with protein replacement therapy, seems to have a relatively lower immunogenicity potential compared to, for example, human coagulation factor VIII. Finally, the disease is very well characterized, small and large animal models of hemophilia B are available, and methods and endpoints to evaluate the efficacy of a given treatment are well established.

The first demonstration that hFIX can be secreted by human hepatocytes following rAAV vector-mediated gene transfer was obtained in a seminal clinical trial where 7 subjects with severe hemophilia B received through the hepatic artery a single-stranded rAAV2 vector carrying the hFIX transgene under the control of a liver-specific promoter (45). The clinical trial was designed with three increasing dose cohorts of $8 \times 10^{10}$ vg/kg, $4 \times 10^{11}$ vg/kg, and $2 \times 10^{12}$ vg/kg, respectively. Therapeutic levels of hFIX expression were reported only in the first patient who received the highest vector dose. However, differently from animal models that showed a stable expression of hFIX over time (51, 112), in humans, transgene expression started to decline 4 weeks after vector injection. This decline was associated with a self-limited increase in liver transaminases and the detection of circulating AAV-specific CD8+ T cells (45, 50). In a second patient dosed at the $2 \times 10^{12}$ vg/kg dose, no transgene expression was observed possibly due to the presence of an anti-AAV2 pre-existing humoral immune response (45).

This first clinical trial demonstrated that the rAAV vectors were safe and efficacious in liver targeting, although transgene expression was only transient. Both small and large animal models used in preclinical research failed to predict this negative outcome linked to an anti-AAV capsid cellular response. Nevertheless, this clinical trial provided unique information for the future use of the rAAV technology for gene transfer in humans. A second clinical trial was then carried out using...
the infusion of up to 6 expression. Similarly, in a clinical trial for hemophilia A, corticosteroids with no measurable decrease in hFIX transgene with the presence of preexisting NAbs, and was treated by with T cells activation detected by ELISPOT, nor correlated was reported in 3 out of 10 patients, was neither associated observed for most of the treated patients. ALT elevation, which liver enzyme elevation on transgene expression in this study has been detected in several participants followed at long-term (114).

In this second trial, participants were screened for pre-existing humoral response against AAV8 and only seronegative patients were included. Three doses of the vector were infused through a peripheral vein ranging from $2 \times 10^{11}$ vg/kg to $2 \times 10^{12}$ vg/kg. Differently from the previous trial, hFIX expression was detectable and reached 1–4% of normal in the low and mid dose cohorts (81). At the highest dose, in the first subject dosed from this cohort, 8 weeks post-infusion the therapeutic hFIX levels (approximately 8–10% of normal) started to decline and, similarly to the previous trial, an elevation of liver enzymes and an increase in circulating capsid-specific T cells was detected. A tapering course of steroids was administered to control the liver enzyme elevation, which allowed for rescue of transgene expression (81). Of the additional participants enrolled in high dose cohort, a total of 6, 4 developed a transient transaminitis that rapidly resolved after transient treatment with prednisolone (74). In this study, in most participants, and in particular those from the high dose cohort, a significant reduction in annualized bleeding episodes in the absence of recombinant hFIX prophylaxis was reported (74) with a stable transgene expression documented for up to 10 years (115).

Results obtained in a third clinical trial for hemophilia B further support the role of the total capsid dose as a determinant of rAAV vector immunogenicity. Subjects seronegative for anti-AAV antibodies received a relatively low dose ($5 \times 10^{11}$ vg/kg) of an AAV vector expressing a hyperactive variant of hFIX (hFIX-R338L). At this dose, only 2 out of 10 participants had an elevation of liver enzymes, which was successfully controlled with corticosteroids. In this study rAAV administration resulted in therapeutic transgene expression in all enrolled subjects (78).

rAAV5 was also used to express hFIX in hepatocytes of hemophilia B patients. This vector, produced in a baculovirus system, was injected at doses up to $2 \times 10^{13}$ vg/kg, in 10 hemophilia B patients (116). Therapeutic levels of hFIX were observed for most of the treated patients. ALT elevation, which was reported in 3 out of 10 patients, was neither associated with T cells activation detected by ELISPOT, nor correlated with the presence of preexisting NAbs, and was treated by corticosteroids with no measurable decrease in hFIX transgene expression. Similarly, in a clinical trial for hemophilia A, the infusion of up to $6 \times 10^{13}$ vg/kg of a rAAV5 vector expressing human coagulation factor VIII resulted in ALT elevation in several enrolled subjects (117). The impact of liver enzyme elevation on transgene expression in this study is being debated, although a decrease in factor VIII levels has been detected in several participants followed at long-term (118).

Corticosteroid treatment given in response to ALT elevation usually controlled the anti-AAV vector immune response and stabilized transgene expression. However, in some cases this approach has failed to control the anti-capsid immune responses. One example is a clinical trial in which 7 hemophilia B subjects received a scAAV8 vector expressing the hyperactive hFIX-R338L variant (119) at doses ranging from $2 \times 10^{11}$ vg/kg to $3 \times 10^{12}$ vg/kg (NCT01687608). Sustained transgene expression (hFIX activity of about 20%) was reached in only one participant, while all other patients enrolled in the trial had either no expression or lost transgene expression despite corticosteroid treatment within 5 to 11 weeks post vector infusion without any evidence of anti-hFIX antibodies formation (120). Vector immunogenicity was possibly dependent on the elevated CpG content of the transgene expression cassette. Indeed, transduction of primary human liver cells with this vector induced the secretion of more Th1-oriented chemokines compared to a CpG-null version of the same vector (121). In a second clinical trial, rAAVRh10 serotype expressing hFIX was administered to six seronegative hemophilia B patients at doses of $1.6 \times 10^{12}$ and $5 \times 10^{12}$ vg/kg (122). A transient expression of hFIX was reported also in this study. After vector administration, 5 out of 6 injected individuals had ALT elevation associated with loss of the transgene expression despite corticosteroid treatment. Four of them demonstrated low anti-capsid and anti-hFIX response as measured by IFN-$\gamma$ ELISPOT assay, possibly reflecting the high doses of corticosteroids they received. Subject 6 had a higher ALT elevation, associated with a strong CD4$^+$ IL-2$^+$ IFN-$\gamma^+$ T cell response against an epitope spanning the hFIX mutation, and increased inflammatory cytokines in the serum (123), however, no anti-hFIX humoral immune response was documented in this subject.

Taken together, the clinical experience accumulated with clinical trials for Hemophilia B indicate that mild immune responses to the vector may clear transgene expression from the liver. These immune responses are controlled by corticosteroid treatment in most of the cases. However, transient expression of the hFIX transgene was observed regardless of corticosteroid treatment in some clinical trials, potentially due to a higher intrinsic immunogenicity of the vectors used.

### AAV Gene Transfer for Neuromuscular Diseases

Neuromuscular diseases of genetic origin are a multitude of diseases that are heterogeneous in terms of pathophysiology, tissues involved, age of onset, and clinical manifestations. Clinical experience accumulated on gene replacement with rAAV vectors indicates that regardless of the disease, muscle or central nervous system targeting requires high vector doses in the range of $1 \times 10^{14}$ vg/kg. In recent years, the improvements in large-scale rAAV vector manufacturing allowed for delivery of the large doses of AAV vectors needed in patients with neuromuscular diseases.
One of the most exciting results in the field of rAAV-mediated gene transfer was the recent approval of Zolgensma (Avexis, Novartis) for the treatment of spinal muscular atrophy (SMA) type I (124). The efficacy of this drug was initially proved in a pivotal clinical trial involving 15 patients with SMA type I (125). A rAAV9 expressing the SMN1 gene under the control of a ubiquitous promoter was infused intravenously at doses of $6.7 \times 10^{13}$ and $2.0 \times 10^{14}$ vg/kg. In the first patient dosed at the low vector dose, a robust ALT elevation (31 times above the upper limit of a normal range) was reported although it was controlled by corticosteroids. After this first observation, prophylactic corticosteroids treatment was applied (30 days, starting 1 day before vector infusion) and ALT elevation was reported only in 3 patients within the high dose group (125). At the same time, high percentage of capsid-specific T cells were detected in peripheral blood by IFN-γ ELISPOT (126). However, neither the ALT elevation nor the presence of capsid-specific T cells was associated with reduced vector efficacy. The excellent efficacy profile and the mild adverse events reported in this first clinical trials were confirmed at long-term (125, 127, 128) and also in a phase III trial (ClinicalTrials.gov: NCT03306277). Based on these results, a dose-finding clinical trial was launched to evaluate the safety and efficacy of intrathecal administration of Zolgensma in SMA type 2 patients (ClinicalTrials.gov: NCT03381729). So far, 31 patients received the treatment at the three vector doses ranging from $6 \times 10^{13}$ to $2.4 \times 10^{14}$ total vector genomes (129). Results of the first two dose cohorts indicated an amelioration of the motor function with mild adverse events. Despite corticosteroids treatment, elevated ALT and AST were reported in one patient and were considered related to the treatment. However, this trial was placed on partial hold by the FDA after the detection of possible toxicity in dorsal root ganglia neurons in two independent preclinical studies performed in large animals (130, 131). Importantly, this unexpected toxicity was never reported in patients that received the same vector by peripheral vein (125) or in a different trial of rAAV gene transfer for giant axonal neuropathy (ClinicalTrials.gov: NCT02362438) in which intrathecal delivery of rAAV9 was associated with transient corticosteroids and a longer course of tacrolimus and rapamycin.

Additional information on the administration of high doses of rAAV in pediatric patients derives from a Phase I/II clinical trial for X-linked myotubular myopathy (MTM, ClinicalTrials.gov: NCT03199469) and three studies for Duchenne muscular dystrophy (DMD, NCT03375164, NCT03362502, NCT03368742). In the MTM study, doses up to $3 \times 10^{14}$ vg/kg of a rAAV8 vector expressing the Mtm1 transgene under the control of a muscle-specific promoter were administered to patients less than 5 years old (132). Clinically meaningful improvement together with robust protein expression and recovered histology were reported. In this study, a prophylactic regimen of corticosteroid was applied. Although the vector was generally well tolerated, increased liver enzymes, creatinine kinase and troponin were reported. Both anti-transgene and anti-capsid immune responses were detected after vector administration, although it is unclear whether there is any correlation with the clinical outcomes. Further studies and long-term follow-up of participants will help to elucidate the relevance of the measured immune responses.

Variable outcomes across trials were reported in the context of systemic rAAV vector delivery for DMD. One clinical trial used a rAAVrh74 vector to express a microdystrophin transgene with the MHCK7 muscle specific promoter (ClinicalTrials.gov: NCT03375164). In this trial, 3 out of 4 DMD patients who received a dose of $2 \times 10^{14}$ vg/kg had elevated liver enzymes, which were controlled by increasing corticosteroid dose (133). So far, no data was provided by the sponsor on specific responses against the capsid or the transgene, although sustained transgene expression, together with amelioration of circulating creatine kinase levels (133), suggest no impact of immune responses on muscle transduction. A randomized, double blind, and placebo-controlled study was recently opened to strengthen the data of this pilot study (ClinicalTrials.gov: NCT03769116). Two weeks after vector injection, a case of rhabdomyolysis was reported in a participant from this second study. However, the study drug safety monitoring board reviewed the data and recommended the study to continue, thus suggesting that the adverse event was possibly unrelated to the investigational product.

Two additional studies of systemic rAAV vector delivery for DMD presented a more complex clinical picture. In the first one, a rAAV9 vector expressing a micro-dystrophin under the control of a muscle-specific promoter was infused intravenously in 6 adolescent patients at two doses, $5 \times 10^{13}$ and $2 \times 10^{14}$ vg/kg (ClinicalTrials.gov: NCT03368742). Despite microdystrophin expression, this trial was placed on hold because 2 patients, one in the low dose and the second in the high dose cohort developed acute kidney injury and activation of the complement system with signs of cardiopulmonary decline (134). In a second trial for DMD, $1 \times 10^{14}$ vg/kg or $3 \times 10^{14}$ vg/kg of an rAAV9 vector expressing a mini-dystrophin under the control of muscle-specific promoter was injected in 6 adolescent patients from 6 to 12 years of age (ClinicalTrials.gov: NCT03362502). Mini-dystrophin expression levels above 20% of wild-type were observed at 2 months post vector infusion, while activation of the immune system, as measured by neutralizing antibody levels and T-cell responses with ELISPOT, was documented in all the participants (135). As in the previous clinical trial, one of the participants showed symptoms of complement activation and acute kidney injury that required a treatment with a complement inhibitor (Eculizumab). Importantly, the sponsor observed that the activation of the complement was associated with a rapid antibody response against the vector (135).

The data obtained from clinical trials in neuromuscular diseases support the concept that high doses of rAAV vectors are in general well tolerated and have the potential to treat
CONCLUSION

In recent years, we have accumulated significant clinical experience with AAV vectors. While the study of immune responses in AAV trials has resulted in important advances for the field, a lot more needs to be done to provide a clear picture of the complex interactions of AAV with the host immune system in the different clinical settings of gene transfer. Of note, relatively little is understood on the host- and vector-dependent factors influencing the development of cytotoxic immune responses leading to poor gene therapy outcomes in terms of duration of transgene expression. To this end, one limitation of the current immunomonitoring methods is that they rely on the in vitro testing of immune cells isolated from peripheral blood vs. lymphocytes infiltrating the peripheral tissues transduced with rAAV vectors. A distinct activation profile of tissue-resident cells, and the variability associated to PBMCs collection and testing across clinical trials (i.e., the lack of standardization of assays used for immunomonitoring), may explain the poor correlation between IFN-γ ELISPOT and immunogenicity outcomes observed in some clinical trials. Additionally, the monitoring of cytokines other than IFN-γ may be helpful in more effectively monitor T cell activation following rAAV vector administration (52) (Figure 3). The relatively low number of subjects enrolled in each trial also represents a potential limitation to the study of immune responses after gene transfer, although the analysis of the collective results in the clinic, along with preclinical studies, has begun to highlight some of the determinants of vector immunogenicity (e.g., the ability of rAAV vectors to activate innate immunity). A more systematic and standardized approach to immunomonitoring in rAAV trials may help further boost our knowledge on vector immunogenicity in humans, particularly for what concerns the understanding of the importance of the disease-specific immune context of gene transfer. This will be key to devise strategies aimed at reliably achieving safe and long-lasting therapeutic efficacy following rAAV vector delivery.

AUTHOR CONTRIBUTIONS

GR, D-AG, and FM wrote the manuscript.

FUNDING

This work was supported by the European Union’s Research Council Consolidator Grant under Grant Agreement No. 617432 (MoMAAV to FM). D-AG was supported by Agence Nationale de la Recherche (ANR-15-CE15-0005-02) and Paris Île-de-France Region (DIM Thérapie Génique).

ACKNOWLEDGMENTS

We thank Dr. Hanako Tsushima for language editing and proofreading the manuscript.
REFERENCES

1. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. (1965) 149:754–6.
2. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol. (1981) 40:241–7.
3. Ogston P, Raj K, Beard P. Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J Virol. (2000) 74:4394–504.
4. Moore AR, Dong B, Chen L, Xiao W. Vaccinia virus as a subhelper for AAV replication and packaging. Mol Ther Methods Clin Dev. (2015) 2:15044. doi: 10.1038/mtm.2015.44.
5. Balakrishnan B, Jayandharan GR. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. (2014) 14:86–100.
6. Ogden PJ, Kelsic ED, Sinai S, Church GM. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science. (2019) 366:1139–43. doi: 10.1126/science.aaw2900.
7. Calcedo R,Morizono H, Wang L,McCartier R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. (2011) 18:1586–8. doi: 10.1128/CVI.01077-11.
8. Erles K,Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. (1999) 59:406–11.
9. Li C,Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, et al. Diverse IgG subclass responses to adeno-associated virus infection resolved by CHS. J Virol. (1998) 72:3494–504.
10. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther. (2008) 15:817–22. doi: 10.1038/gt.2008.55.
11. Matsushita T,Elgger S, Elliger C,Podsakoff G,Villarel R,Kurtzman GJ, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. (1998) 5:938–45.
12. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. (1998) 9:2745–60.
13. Gao GP,Qu G, Faust LZ,Engdahl RK,Xiao W,Hughes JV, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther. (1998) 9:2353–62.
14. Conway JE,Zolotukhin S,Muzyczka N,Naylor GS,Byrne BJ, Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amphotropic expressing Rep and Cap. J Virol. (1997) 71:8780–9.
15. Thomas DL, Wang L,Niamke J,Liu J,Kang W,Scotti MM, et al. Scalable recombinant adeno-associated virus vector production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther. (2009) 20:861–70. doi: 10.1089/hum.2009.004.
16. Marek M,van Oers MM,Devaraj FJ, Vlak JM,Merten OW. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol Bioeng. (2011) 108:1056–67. doi: 10.1002/bit.23028.
17. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. (2008) 15:840–8. doi: 10.1038/gt.2008.65.
18. Grieger JC,Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. (2012) 507:229–54. doi: 10.1016/B978-0-12-386509-0.00012-0.
19. Ayuso EMingozi F, Montane J,Leon X,Aguela XM,Haurigot V, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. (2010) 17:503–10. doi: 10.1038/gt.2009.157.
20. Penaud-Budloo M,François A, Clément N, Ayuso E. Pharmacology of recombinant adeno-associated virus production. Mol Ther Methods Clin Dev. (2018) 8:1666–80. doi: 10.1016/j.omtm.2018.01.002.
21. Wright JF,Wellman J,High KA. Manufacturing and regulatory strategies for clinical AAV-2-HRPE65. Curr Gene Ther. (2010) 10:341–9.
22. Ayuso EMingozi F,Bosch F. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther. (2010) 10:423–36.
23. Xiang Z,Kurupati RK, Li Y, Kuranda K,Zhou X, Mingozi F, et al. The effect of Caps on capsid-specific CD8(+) T cell responses to AAV vector gene transfer. Mol Ther. (2019) 27:771–83. doi: 10.1016/j.ymthe.2019.11.014.
24. McCoy RT, Selkoe DJ, Wellman J, High KA. Manufacturing and regulatory strategies for clinical AAV-2-HRPE65. Curr Gene Ther. (2010) 10:341–9.
25. Xiang Z,Kurupati RK, Li Y, Kuranda K,Zhou X, Mingozi F, et al. The effect of Caps on capsid-specific CD8(+) T cell responses to AAV vector gene transfer. Mol Ther. (2019) 27:771–83. doi: 10.1016/j.ymthe.2019.11.014.
26. McCoy RT, Selfe DJ, Wellman J, High KA. Manufacturing and regulatory strategies for clinical AAV-2-HRPE65. Curr Gene Ther. (2010) 10:341–9.
27. Xiang Z,Kurupati RK, Li Y, Kuranda K,Zhou X, Mingozi F, et al. The effect of Caps on capsid-specific CD8(+) T cell responses to AAV vector gene transfer. Mol Ther. (2019) 27:771–83. doi: 10.1016/j.ymthe.2019.11.014.
51. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Successful transfer of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. (2006) 12:342–7.

52. Kuranda K, Jean-Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Analysis of humoral, innate, and adaptive immune responses to adenovirus vectors. J Virol. (2008) 82:2727–40. doi: 10.1128/JVI.01990-07

53. Scallon CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2-neutralizing titers in SCID mice. Blood. (2006) 107:1810–7.

54. Walport MJ. Complement. First of two parts. N Engl J Med. (2001) 344:1058–66.

55. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. Evaluation of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 capsid proteins. Mol Ther. (2007) 15:7540–7.

56. Hui DJ, Edmonson SC, Podsakoff GM, Pien GC, Ivanciu L, Camire RM, et al. Intravascular delivery of the truncated AAV9 capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. J Immunol. (2015) 194:2199–204. doi: 10.1159/000369273

57. Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System, 3rd ed. Philadelphia, PA: Saunders. (2009).

58. Calcedo R, Chichester JA, Wilson JM. Assessment of humoral, innate, and T-cell immune responses to adenovirus vectors. Hum Gene Ther Methods. (2018) 29:86–95. doi: 10.1089/hgtb.2018.038

59. Hui DJ, Edmonson SC, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Effects of transient immunosuppression on adeno-associated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. (2006) 108:3321–8.

60. Chichester JA, Patarroyo-White S, Liu T, Rosenfeld J, Nagy D, Vargas JA, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2-neutralizing titers in SCID mice. Blood. (2006) 107:1810–7.

61. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryal RC, Moghimi B, et al. The genome of self-complementary adenovirus vector increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. (2011) 117:6549–68. doi: 10.1182/blood-2010-10-314518

62. Shao W, Earley LF, Chai Z, Chen X, Sun J, He T, et al. Double-stranded RNA innate immune response activation from long-term adenovirus-associated vector transduction. JCI Insight. (2018) 3:e120474. doi: 10.1172/jci.insight.120474

63. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector gene transfer. Cell Immunol. (2019) 342:103682. doi: 10.1016/j.cellimm.2017.07.012

64. Rogers GL, Shirley JL, Zolotukhin I, Kumar SRP, Sherman A, Perrin GQ, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Mol Ther Methods Clin Dev. (2014) 1:14033.

65. Palaschak B, Marsic D, Herzog RW, Zolotukhin S, Markusic DM. An immune-competent murine model to study elimination of AAV-transduced hepatocytes by capsid-specific CD8+ T cells. Mol Ther Methods Clin Dev. (2017) 5:142–52. doi: 10.1016/j.omtm.2017.04.004

66. Reiss UM, Zolotukhin S, Markusic DM, Perrin GQ, Barron TJ, Perrin GQ, et al. Type I IFN sensing by cDCs and CD4+ T cell help are both requisite for cross-priming of AAV capsid-specific CD8+ T Cells. Mol Ther. (2019) 27:758–70. doi: 10.1016/j.ymther.2019.11.011

67. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. Regulation of tolerance to the transgene product in a nonparenchymal liver cell-directed gene transfer in rhesus macaques and implications for human gene therapy. Mol Ther. (2014) 1:14033.
82. Mingozzi F, Meullenberg JJ, Hui DJ, Basner-Tschakarjan E, Hashbrouck NC, Edmonson SA, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. *Blood*. (2009) 114:2077–86. doi: 10.1182/blood-2008-07-167510
83. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, Mingozzi F, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. *Mol Ther*. (2010) 18:135–42. doi: 10.1038/mt.2009.257

84. Greig JA, Calvedo R, Kuri-Cervantes L, Nordin JML, Albrecht J, Bote E, et al. AAV8 gene therapy for crigler-najjar syndrome in macaques elicited transgene T cell responses that are resident to the liver. *Mol Ther Methods Clin Dev*. (2018) 11:191–201. doi: 10.1016/j.omtm.2018.10.012
85. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunochemistry in Duchenne muscular dystrophy. *N Engl J Med*. (2010) 363:1429–37. doi: 10.1056/NEJMoa1000228

86. Calvedo R, Somananthan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, et al. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1 antitrypsin deficiency. *Proc Natl Acad Sci USA*. (2017) 114:1655–9. doi: 10.1073/pnas.1617276114
87. Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calvedo R, et al. 5 Year Expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. *Mol Ther*. (2017) 25:1387–94. doi: 10.1038/ymthe.2017.03.029

88. Tardieu M, Zéra M, Gougeon ML, Asseil J, de Bournonville S, Husson B, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIH syndrome: an uncontrolled phase 1/2 clinical trial. *Lancet Neurol*. (2017) 16:712–20. doi: 10.1016/S1474-4422(17)30169-2
89. Poupiot J, Costa Verdera H, Sahenk Z, Shilling C, Lewis S, et al. Gene therapy-induced antigen-specific Tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis. *Mol Ther*. (2018) 26:173–83. doi: 10.1038/ymthe.2017.09.001

90. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. *J Clin Invest*. (2008) 113:797–806. doi: 10.1182/blood-2007-10-119403
91. Benseler V, Warren A, Vo M, Holz LE, Tay SS, Le Couteur DG, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. *J Leukoc Biol*. (2014) 96:571–7. doi: 10.1189/jlb.1B0613-342BR

92. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene therapy. *Blood*. (2004) 104:969–77.
93. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Multiyear Follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A. *J Hepatol*. (2018) 131:1022–31. doi: 10.1182/blood-2017-09-804419
94. Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens REH, et al. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1 antitrypsin deficiency. *J Immunol*. (2004) 172:1009–17.

95. Kumar SRP, Hoffman BE, Terhorst C, de Jong YP, Herzog RW. The balance between CD8+ T Cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose. *Mol Ther*. (2017) 25:880–91. doi: 10.1016/j.ymthe.2017.02.014
96. Tay SS, Wong YC, McDonald DM, Wood NA, Roediger B, Sierra F, et al. Antigen expression level threshold tunes the fate of CD8+ T cells during primary hepatic immune responses. *Proc Natl Acad Sci USA*. (2014) 111:E2540–9. doi: 10.1073/pnas.1406674111

97. Holz LE, Benseler V, Bowen DG, Bouillet P, Strasser A, O’Reilly L, et al. Intrathecal murine dendritic cell T-cell activation associates with a distinct phenotype leading to Bim-dependent death. *Gastroenterology*. (2008) 135:989–97. doi: 10.1016/j.gastro.2008.05.078

98. Keeler GD, Kumar S, Palaschak B, Silverberg EL, Markusic DM, Jones NT, et al. Gene therapy-induced antigen-specific tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis. *Mol Ther*. (2018) 26:173–83. doi: 10.1038/ymthe.2017.09.001
99. Le Guen V, Judor JP, Boefurd F, Gauthier V, Ferry N, Soulillou JP, et al. Allotrangenic gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8+ regulatory T cells. *J Hepatol*. (2017) 66:765–77. doi: 10.1016/j.jhep.2016.11.019
100. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. *Blood*. (2004) 104:969–77.
101. Kumar S, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. *Blood*. (2009) 113:797–806. doi: 10.1182/blood-2008-10-181479
102. Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens REH, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. *Blood*. (2007) 109:1414–21.
103. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther*. (2001) 8:1248–54.
104. Reiss UM. AAV8-FIX long term follow up and future plans, in Proceedings of the Oral Presentation National Hemophilia Foundation’s 15th Workshop on Novel Technologies and Gene Transfer for Hemophilia 2019. Washington, DC: National Hemophilia Foundation. (2019).
105. Siemesch M, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. *Blood*. (2018) 131:1022–31. doi: 10.1182/blood-2017-09-804419
106. Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5-Factor VIII Gene transfer in severe Hemophilia A. *N Engl J Med*. (2017) 377:2519–30. doi: 10.1056/NEJMoa1708483
107. Pinski RJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, et al. Multimyr Follow-up of AAV5-FvIII-SQ gene therapy for Hemophilia A. *N Engl J Med*. (2020) 382:29–40. doi: 10.1056/NEJMoa1908490
108. Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting
an ongoing adeno-associated virus clinical trial. *Hum Gene Ther.* (2015) 26:69–81. doi: 10.1089/hum.2014.106

120. Blici I, Monahan P, Berg V, Scheiffinger F, Reipert BM. Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy reveals potential determinants of persistent transgene expression. *Res Pract Thromb Haemost.* (2019) 3(Suppl. 1):95

121. Koppensteiner H, Hartleib B, Frentsch M, Dingeldey M, Horling F, Horling FM, et al. Increased immunogenicity of CpG containing adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression. *Res Pract Thromb Haemost.* (2019) 3(Suppl. 1):302.

122. Pipe S, Stine K, Rajasekhar A, Everington T, Poma A, Crombez E, et al. 101HEMB01 is a phase 1/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate/severe Hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX). *Blood.* (2017) 130(Suppl. 1):3331.

123. Calcedo R, Kuri-Cervantes L, Peng H, Qin Q, Boyd S, Schneider M, et al. Immune responses in 101HEMB01, a Phase 1/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with severe Hemophilia B. *Blood.* (2017) 130(Suppl. 1):3333.

124. Hoy SM. Onasemnogene abeparvovec: first global approval. *Drugs.* (2019) 79:1255–62. doi: 10.1007/s40265-019-01162-5

125. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med.* (2017) 377:1713–22. doi: 10.1056/NEJMoal706198

126. Mendell JR, Al-Zaidy S, Shell R, Burghes AHM, Foust KD, Kaspar BK, et al. Gene therapy for spinal muscular atrophy Type 1 shows potential to improve survival and motor functional outcomes. *Mol Ther.* (2016) 24(Suppl. 1):S190.

127. Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, et al. Impact of age and motor function in a phase 1/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy. *Pediatr Neurol.* (2019) 98:39–45. doi: 10.1016/j.pediatrneurol.2019.05.005

128. Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol.* (2019) 54:179–85. doi: 10.1002/ppul.24203

129. Finkel R, Day J, Darras B, Kuntz N, Connolly A, Crawford T, et al. Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1/2a study (STRONG). *Neuromuscul Disord.* (2019) 29(Suppl. 1):S207.

130. Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. *Hum Gene Ther.* (2018) 29:285–98. doi: 10.1089/hum.2018.015

131. cureSMA. AveXis Issues Community Statement on AVXS-101 Clinical Hold. (2019). Available online at: https://www.curesma.org/avexis-community-statement-clinical-hold2019/ (accessed December 04, 2019)

132. Dowling J. ASPIRO phase 1/2 gene therapy trial in X-linked motubular myopathy (XLMTM): update on preliminary safety and efficacy findings. 24th World Muscle Society Meeting 2019. *Neuromuscul Disord.* (2019) 29:S37–S208.

133. Rodino-Klapac L. Neuromuscular targeted therapies, in *Proceedings of the 22nd Annual Meeting: Final Program Guide.* Washington, DC: American Society of Gene & Cell Therapy. (2019).

134. Solid Biosciences Inc. *Solid Biosciences Provides SGT-001 Program Update.* Cambridge, MA: Solid Biosciences Inc. (2019).

135. Pfizer Inc. *Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD).* New York, NY: Pfizer Inc. (2019).

Conflict of Interest: FM was employed by Spark Therapeutics, a Roche company. FM and GR are inventors in patents related to AAV gene therapy and the control of immune responses against AAV vectors.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ronzitti, Gross and Mingozzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.